This conclusion has been supported by a comparison between FTD-TDP and a small group of “definite” FTD-Tau cases (definite PSP, CBD, and MAPT carriers) which revealed no differences. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.